Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Li Tong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Research Project Foundation of Anhui Province, Anhui Medical University General Surgery and Cell Biology Joint Project Foundation.
Abstract (Originalsprache)
Ubiquitin A‐52 residue ribosomal protein fusion product 1 (UBA52) has a role in the occurrence and development of tumours. However, the mechanism by which UBA52 regulates hepatocellular carcinoma (HCC) tumorigenesis and progression remains poorly understood. By using the Cell Counting Kit (CCK‐8), colony formation, wound healing and Transwell assays, we assessed the effects of UBA52 knockdown and overexpression on the proliferation and migration of HCC cells in vitro. By establishing subcutaneous and metastatic tumour models in nude mice, we evaluated the effects of UBA52 on HCC cell proliferation and migration in vivo. Through bioinformatic analysis of data from the Gene Expression Profiling Interactive Analysis (GEPIA) and The Cancer Genome Atlas (TCGA) databases, we discovered that UBA52 is associated with autophagy. In addition, we discovered that HCC tissues with high UBA52 expression had a poor prognosis in patients. Moreover, knockdown of UBA52 reduced HCC cell growth and metastasis both in vitro and in vivo. Mechanistically, knockdown of UBA52 induced autophagy through EMC6 in HCC cells. These findings suggest that UBA52 promoted the proliferation and migration of HCC cells through autophagy regulation via EMC6 and imply that UBA52 may be a viable novel treatment target for HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- College of Life Sciences of Anhui Medical University, Hefei, China.
ORCID-Profile: Chao Zhang
Förderung
- University Research Project Foundation of Anhui Province
- Anhui Medical University General Surgery and Cell Biology Joint Project Foundation
Zitieren
APA
Tong, L., Zheng, X., Wang, T., Gu, W., Shen, T., Yuan, W., Wang, S., Xing, S., Liu, X., Zhang, C., & Zhang, C. (2024). Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18164
Vancouver
Tong L, Zheng X, Wang T, Gu W, Shen T, Yuan W, et al. Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18164
BibTeX
@article{Tong2024,
author = {Tong, Li and Zheng, Xiaofei and Wang, Tianqi and Gu, Wang and Shen, Tingting and Yuan, Wenkang and Wang, Siyu and Xing, Songlin and Liu, Xiaoying and Zhang, Chong and Zhang, Chao},
title = {Inhibition of UBA52 induces autophagy via EMC6 to suppress hepatocellular carcinoma tumorigenesis and progression},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18164}
}
EUVIMED